Drug intelligence / Profile preview

estradiol + norethindrone acetate + selective serotonin reuptake inhibitors

Development stage
Unknown
Lead developer
AbbVie
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

This is a combination of three pharmacological agents: - **Estradiol** is a synthetic form of the primary female sex hormone estrogen, used in hormone replacement therapy to alleviate menopausal symptoms and prevent osteoporosis by replacing declining endogenous estrogen levels. - **Norethindrone acetate** is a synthetic progestin (a form of progesterone) that counteracts the effects of unopposed estrogen on the endometrium, reducing the risk of endometrial hyperplasia and cancer when used with estradiol. This combination (estradiol + norethindrone acetate) is commonly prescribed for moderate to severe menopausal symptoms such as hot flashes, night sweats, vaginal atrophy, and for osteoporosis prevention in postmenopausal women[1][2][3][4]. - **Selective serotonin reuptake inhibitors (SSRIs)** are a class of antidepressant medications that increase synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons. SSRIs are primarily indicated for major depressive disorder, anxiety disorders, obsessive-compulsive disorder, and other psychiatric conditions. There is no evidence from available sources that these three agents are co-formulated or marketed as a single pharmaceutical product; rather, they may be co-prescribed in clinical practice for patients who require both hormone replacement therapy and treatment with an SSRI.

02

Targets

SERT (Sodium-dependent serotonin transporter)PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on estradiol + norethindrone acetate + selective serotonin reuptake inhibitors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on estradiol + norethindrone acetate + selective serotonin reuptake inhibitors.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call